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Salvatore Amoroso1* and Gian Piero Perna2Abstract
Background: Drugs not commonly considered to be cardioactive agents may cause prolongation of the QT
interval with resultant torsades de pointes and ventricular fibrillation. This form of drug toxicity often causes cardiac
arrest or sudden death.
Case presentation: After accidental ingestion of tosylchloramide a caucasian 77-year-old woman, with a family
history of cardiovascular disease and hypertension, was admitted to the intensive care unit following episodes of
torsades de pointes with a prolonged QT/QTc interval (640/542 ms). The patient received an implantable
cardioverter-defibrillator, was discharged from the hospital with normal QT/QTc interval and did not experience
additional ventricular arrhythmias during one year of follow-up.
Conclusion: This is the first report concerning an unusual case of torsades de pointes after accidental intoxication
by ingestion of tosylchloramide. The pronounced impact of the oxidyzing agent tosylchloramide on the activity of
some of the ion channels regulating the QT interval was identified as a probable cause of the arrhythmia.
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Because of its high activity against fungi and bacteria,
tosylchloramide is a widely used disinfectant agent for
common applications such household cleaning and
swimming pool disinfection. Many case reports describ-
ing tosylchloramide intoxication have been already pub-
lished in the past showing that the chronic exposure to
this compound may cause hypersensitivity reactions,
such as asthma [1,2], conjunctivitis [3], whereas toxic
pneumonitis [4], cardiovascular collapse and myocardial
damage may occur in acutely intoxicated patients [5].
Here we report the first case of a severe arrhythmia
developed in the context of acute oral intoxication with
tosylchloramide.Case presentation
A 77-year-old woman presenting shoulder girdle pain
was admitted to our hospital with suspected coronary* Correspondence: s.amoroso@univpm.it
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reproduction in any medium, provided the orsyndrome. She had a history of hypertension; treated
since 5 years with Perindopril (5 mg once daily) and a
family history of cardiovascular disease. Few hours after
the admission at the Emergency Room (ER) the patient
experienced a cardiac arrest due to a “Torsade de
Pointes” (TdP) degenerated into ventricular fibrillation
which required DC shock (200 J), as documented by
electrocardiogram (ECG) (Figure 1). After specific ques-
tioning for drug intake, the patient revealed She had ac-
cidentally (non-intentionally) ingested an entire sachet
of Euclorina (containing 2.5 g of tosylchloramide) be-
tween 5 and 6 hours before TdP.
Surface ECG on admission in ER showed sinus rhythm
with pre-existing left bundle branch block (LBBB).
Serum potassium was in slightly lower normal range
(3.3 mEq/l, before 3.8 mEq/l), while other haemato-
logical parameters were in their respective reference
intervals (data not shown). On admission to the cardi-
ology Intensive Care Unit (ICU) the ECG disclosed sinus
bradycardia (55 bpm) with significant alteration in the
QT interval (QT/QTc = 640/543 msec; Figure 2) that
was significantly prolonged over a 24-hour period.
Thereafter the patient underwent an echocardiographyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 TDP with fast degeneration into Ventricular Fibrillation. The ECG-strip pre-TDP (Figure1A) shows a QT interval of 640 msec
(QTc is 542 msec).
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mild reduction in global systolic function (LVEF = 50%)
due to LBBB-induced dyssynergy of the interventricular
anterior septum wall.
The middle left anterior descending coronary artery
(LAD) had a non-significant stenosis (< 50%) as revealedby coronary angiography and IVUS control (Figure 3). A
not significant stenosis was detected in a non-dominant
right coronary artery (Figure 3). According to the criteria
defined in Thygesen et al. [6], myocardial infarction was
excluded for the following reasons: a) no symptoms or
electrocardiographic changes were detected; b) the peak
Figure 2 ECG at the admission to ICU shows a LBBB with a prolonged QT/QTc interval (640–542 msec).
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in our laboratory is < 5 ng/ml) only after 6 h from DC
shock, and normalized (3.2 ng/ml) within the following
6 h; c) the peak Troponin I level was 0.32 ng/ml (the
normal reference value in our laboratory is < 0.08 ng/ml)
6 h after DC shock, and normalized (0.06 ng/ml) 6 h later.
No signs of liver or kidney derangement were observed
(data not shown).
The patient was discharged 7 days after admission, fol-
lowing the placement of an implantable cardioverter-
defibrillator (ICD); the ECG at discharge showed a LBBB
with a normal QT interval (QT/QTc = 400/430 msec;
Figure 4). After 12 and 24 months of follow-up She has
been clinically stable, no shock detected at ICD registra-
tion and her QT interval was normal (Figure 5).
Discussion
The occurrence of TdP in our patient after tosylchlora-
mide ingestion can be explained considering that this
compound acts as a strong oxidant of methionines and
cysteines residues in proteins [7]. The activity of some of
the ion channels regulating the duration of the QT inter-
val is, indeed, strongly influenced by oxydation of critical
methionine residues in channel proteins. In particular,
voltage-dependent inactivation of NaV channels is signifi-
cantly slowed down when methionine residues located
in the so called IMF domain, which is responsible forvoltage-dependent channel inactivation, are oxydized [8].
Consistently, tosylchloramide, which has a strong prefer-
ence in oxydizing methionine residues [9], is one of the
most powerful oxydants affecting NaV channel inactiva-
tion [9,10] and it has been used as a pharmacological
tool to abolish voltage-dependent inactivation in studies
aiming to determine its contribution in the activity of
specific cardiovascular drugs [11]. Tosylchloramide-
induced slowing of NaV channel inactivation is a quite
general phenomenon being observed in the brain, muscle
and, importantly, cardiac isoform of these channels [8].
Oxydant-induced impairment of NaV voltage-dependent
inactivation may per se explain the appearance of TdP in
our patient intoxicated with tosylchloramide since it
causes a marked increase in persistent INa (INaP )
[12,13], the inactivation-resistant Na+ current which
persists in the presence of prolonged membrane
depolarization [14]. An increase in INaP is, indeed, a
well documented mechanism of QT prolongation and
arrhythmogenesis and a potentailly relevant target for
treatment and prevention of arrhythmias [15,16]. In
addition, an increase in INaP is considered responsible
for arrhythmogenesis in patients affected with the
LQT3 syndrome which bear specific mutations in the
NaV1.5 channel gene [17-19]. Confirming the involvement
of INaP in oxydant-induced arrhythmogenesis, the INaP
blocker ranolazine was effective in preventing QT
Figure 3 Coronary Angiography. No significant CAD is detected
in right cororary artery. The middle left anterior descending coronary
artery had a non-significant stenosis (< 50%), as confirmed by
IVUS control.
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strong oxydant agent H2O2 in cultured guinea pig cardio-
myocytes [13]. Therefore, it is tempting to speculate that, in
our patient, tosylchloramide exposure recapitulated the
pathophysiological mechanism of cardiac arrhythmia in
LQT3 patients.
hERG is another oxydation-sensitive ion channel that
could have been involved in the genesis of TdP in our
patient. hERG is the main K+ current responsible for
rapid repolarization of cardiac myocytes in phase III ofcardiac action potential [20] and its loss of function is
one of the best characterized mechanisms of drug-
induced or congenital LQT syndrome [21]. Specifically,
mutations causing either loss of function or alterations
in trafficking of hERG channels are responsible for the
LQT2 syndrome [22,23] whereas mutations in MiRP1,
an accessory subunit that coassembles with hERG, have
been found in LQT6 patients [24]. Intriguingly, by oxy-
dizing critical methionine residues, tosylchloramide
causes an almost complete loss of hERG channel activity
in vitro [25] thus reproducing the effect of drugs or
mutations known to cause TdP. Therefore, it is likely
that hERG channel blockade could have played a role in
the appearance of TdP in our patient.
Finally, it is worth to remind that several oxydants, in-
cluding tosylchloramide, may also increase the activity of
L-type voltage-gated Ca2+ channels (VGCC), even though,
in this case, the specific inolvement of methionine resi-
dues has not been demonstrated [26,27]. By increasing
Ca2+ influx through L-type VGCC, tosylchloramide is
expected to prolong the plateau phase of cardiac action
potential thus delaying cardiomyocyte repolarization
and promoting the appearance of TdP. Intriguingly, an
increase in L-type VGCC activity represents the mech-
anistic base of arrhythmias in LQT8 patients [28-30]
bearing the Timothy syndrome mutations which cause
an impairment in voltage-dependent CaV1.2 channel
inactivation [31].Conclusion
Oxidative stress has been proposed as one of the up-
stream events provoking clinical relevant arrhythmic
responses [32] and several drugs used in therapy exert
antiarrhythmic effects in part via their antioxidative
property [33,34]. Here we suggest that severe arrhythmia
may occur in the form of TdP after massive exposure to
the oxidizing agent tosylchloramide. In fact, tosylchlora-
mide has a pronounced impact on the activity of some
of the ion channels regulating the QT interval. Since
our patient exhibited no evidence of QT interval alter-
ation after 12 and 24 months of follow-up, this strongly
suggests a causal role of tosylchloramide intoxication
for the ECG abnormalities occurred during observation
in the ICU. Therefore, a strict electrocardiographic
monitoring is advised in patients intoxicated with this
compound.Consent
Written informed consent was obtained from the patient
prior to publication of this case report and any accom-
panying images. A copy of the written consent is avail-
able for review by the Series Editor of this journal.
Figure 4 ECG at hospital discharge. QT interval measures 400 msec, the QTc interval 430 msec.
Figure 5 ECG at 1-year follow-up shows stable LBBB and normal QT/QTc interval (405/432 msec).
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